Русский
Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia
DOI: https://dx.doi.org/10.18565/urology.2019.2.73-81
A.A. Kamalov, L.M. Samokhodskaya, V.K. Karpov, D.A. Okhobotov, V.N. Mamedov
1) Faculty of Fundamental Medicine of Lomonosov Moscow State University, Department of Urology and Andrology (Head of Department – academician of the RAS, MD, Kamalov A.A.), Moscow, Russia; 2) Medical Scientific and Educational Center of Lomonosov Moscow State University (Chief – academician of the RAS, MD, Kamalov A.A.), Moscow, Russia; 3) GBUZ “City Clinical Hospital №31” of Moscow City Department of Health (Chief – Ph.D. Efremova N.M.), Moscow, Russia
Prostate cancer (PCa) is the 4th most commonly diagnosed cancer in the male population and incidence of different stages is increasing every year. The efficiency of PCa treatment is strongly dependent on the its stage. Prostate Specific Antigen (PSA) is the most widely used and universal biomarker of PCa worldwide. Considering its limited predictive value, particularly in patients older than 50 with PSA level ranging from 4.5 to 10 ng/ml, there is a need to introduce new serum biomarkers of PCa. Current data on different PCa biomarkers are reviewed in the article as well as a role of angiotensin-converting enzyme (ACE) as a novel PCa biomarker.
About the Autors
Corresponding author: V.N. Mamedov – Ph.D. student, Department of Urology and Andrology of Department of Urology and Andrology, Faculty of Fundamental Medicine of Moscow State University by Lomonosov, Moscow, Russia; e-mail: mvadim_91@yahoo.com
